Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Sana Biotechnology in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst E. Bodnar ...

Sana Biotechnology operates in a highly competitive and rapidly evolving biotechnology sector. With a beta of 1.64 according to InvestingPro, the stock exhibits higher volatility than the broader ...

Sana Biotechnology (NASDAQ:SANA – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a ...

Asana stock remains challenged in the face of CEO Dustin Moskovitz’s sudden retirement and a downbeat outlook for the current ...

Pre-earnings options volume in Sana Biotechnology (SANA) is 2.0x normal with calls leading puts 150:1. Implied volatility suggests the market ...

Sana Biotechnology operates in a highly competitive and rapidly evolving biotechnology sector. With a beta of 1.64 according to InvestingPro, the stock exhibits higher volatility than the broader ...

On Tuesday, Sana Biotechnology shares received an upgrade from Citizens JMP, shifting the company’s stock rating from Market Perform to Market Outperform. The biotechnology firm, traded under ...

Sana Biotechnology SANA, a clinical-stage company, is expected to report its fourth-quarter results soon. The company leverages its proprietary hypoimmune technology to develop cell engineering ...